Bristol Gate Capital Partners Inc. Has $83.40 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bristol Gate Capital Partners Inc. lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 160,304 shares of the medical research company's stock after selling 3,745 shares during the quarter. Thermo Fisher Scientific accounts for 4.1% of Bristol Gate Capital Partners Inc.'s investment portfolio, making the stock its 18th biggest position. Bristol Gate Capital Partners Inc.'s holdings in Thermo Fisher Scientific were worth $83,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of TMO. Geode Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock worth $4,719,477,000 after buying an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 11.4% in the third quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after acquiring an additional 995 shares in the last quarter. Greenwood Gearhart Inc. grew its stake in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after purchasing an additional 1,837 shares in the last quarter. Nordea Investment Management AB increased its holdings in Thermo Fisher Scientific by 23.6% during the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after purchasing an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC boosted its stake in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after buying an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $10.47 during midday trading on Friday, reaching $437.91. The stock had a trading volume of 2,656,544 shares, compared to its average volume of 1,696,843. The firm's 50 day moving average price is $510.56 and its 200-day moving average price is $539.34. Thermo Fisher Scientific Inc. has a 52 week low of $409.85 and a 52 week high of $627.88. The company has a market capitalization of $165.21 billion, a P/E ratio of 26.49, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.39%. Thermo Fisher Scientific's payout ratio is 10.41%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 in the last quarter. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. UBS Group upped their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a report on Friday, January 31st. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a research report on Friday, January 10th. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Scotiabank boosted their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Finally, StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $647.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.